Celularity Inc. (CELU) Stock

Celularity Inc. (CELU) is a Healthcare stock trading at $1.05 (as of 2026-06-03), with a market capitalization of $20.29M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Celularity Inc. develops placental-derived allogeneic cell therapy products for cancer, immune, and infectious disease indications. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments, with programs including CYCART-19 and CYNK-001/CYNK-101 in clinical studies and stromal-cell candidates in pre-clinical stages.

Understand Celularity Inc.: how it makes money

Celularity develops off-the-shelf placental-derived allogeneic cell therapies for cancer, immune, and infectious diseases, it currently has no reported commercial revenue (latest-quarter revenue is 0.0B).

Because its lead programs are in early clinical stages (Phase I, with CYNK-001 also in Phase I/II) and the latest quarter shows 0.0B revenue, the profit model depends primarily on clinical trial progress that can ultimately enable future approval and commercialization.

Business quality (Weak): Clear therapeutic focus and defined programs, but the current financial profile is loss-making and driven by ongoing development rather than sales (revenue 0.0B in the latest quarter).

Bull case

  • Multiple early-stage programs in the same placental-derived allogeneic cell-therapy approach: CYCART-19 (Phase I for B-cell malignancies) and CYNK-001 (Phase I for acute myeloid leukemia, and also in Phase I/II as described).
  • Off-the-shelf positioning: The company develops off-the-shelf placental-derived allogeneic cell therapies, which is a specific therapeutic model aimed at scalability.

Bear case

  • No reported commercial revenue in the latest quarter: The latest-quarter revenue is 0.0B, so performance is not coming from product sales.
  • Execution and timing risk from early-stage clinical development: Lead programs are in Phase I (and CYNK-001 is also described as Phase I/II), which leaves material uncertainty around outcomes and progression.
  • Deeply negative operating profitability in the latest quarter: Operating margin is -244.1% in the latest quarter, indicating substantial costs relative to revenue.
Valuation — source: SEC EDGAR (first-party)
Price$1.05
Market Cap$20.29M
EV / EBITDA-0.2
Price / Book-0.53
Price / Sales0.76
FCF Yield-66.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$26.55M
Net Margin-345.4%
Return on Equity241.0%
Debt / Equity-0.17
Current Ratio0.15
Revenue Growth (YoY)-51.0%
EPS Growth (YoY)36.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-15.21 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderC V STARR & CO INC ($1.02M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORobert Joseph Hariri
Employees120
CountryUS
IPO Date2019-08-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Marker Therapeutics, Inc. (MRKR)
  • Allarity Therapeutics, Inc. (ALLR)
  • Biofrontera Inc. (BFRI)
  • Cocrystal Pharma, Inc. (COCP)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Cyclerion Therapeutics, Inc. (CYCN)
  • Tvardi Therapeutics, Inc. (TVRD)
  • Tempest Therapeutics, Inc. (TPST)
CELU earnings history · CELU institutional & insider holders · CELU KPIs & operating metrics · CELU financials · CELU investor presentations & press releases · CELU SEC filings · CELU peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-03.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.